NAMD

Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting

Retrieved on: 
Thursday, June 2, 2022
Compliance, Retina, Severe cognitive impairment, Lance, Program, Macular degeneration, Neovascularization, Eye, Macula of retina, AMD, VEGF, Annual general meeting, Nasdaq, OPTIC, NAMD, GLOBE, Patient, Private Securities Litigation Reform Act, Publication, Technology, Weill Cornell Medicine, Research, Incidence, SEC, Prevalence, IVT, Dean (education), Degenerative disease, U.S. Securities and Exchange Commission, Safety, Vaccine, Pharmaceutical industry, Ophthalmology, Adverum Biotechnologies

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data from the Phase 1 OPTIC study ADVM-022 (AAV.7m8-aflibercept) development program in wet age-related macular degeneration (wet AMD) will be presented during the Macula Society’s 2022 Annual Meeting in Berlin, Germany. The presentation will include an update on aflibercept protein expression data through three years post-treatment. In addition, a new analysis will compare the anatomical outcomes of a single intravitreal injection of ADVM-022 to standard-of-care bolus anti-vascular endothelial growth factor (VEGF) therapy in patients with wet AMD and will include an evaluation of the impact of baseline levels of neutralizing antibodies (NAbs) to AAV.7m8 on ADVM-022 efficacy, safety, and anatomical measures.

Key Points: 
  • The presentation will include an update on aflibercept protein expression data through three years post-treatment.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Insights on the Anti-Vascular Endothelial Growth Factor Therapeutics Global Market to 2030 - Featuring Amgen, Bausch Health Companies and Coherus Biosciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
General Health, Pharmaceutical, Optical, Health, Eli Lilly, Eye, Hoffmann-La Roche, US, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Neovascularization, US Foods, Ageing, MedImmune, Inc. v. Genentech, Inc., AMD, Therapy, Ranibizumab, US FDA, Optic nerve, NAMD, FDA, 938, Industry, Diabetic retinopathy, Faricimab, Vance DeGeneres, Pfizer, ABP, USD, Pharmaceutical industry, Fine chemical, Disease

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.

Key Points: 
  • The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 13.32 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The anti-vascular endothelial development aspect therapeutics industry is growing due to new product releases, FDA approvals, and research developments.
  • Market players such as Bausch Health Companies, Inc., Viatris, Inc., Amgen, Inc., Coherus Biosciences, Eli Lilly, F. Genentech Inc., Hoffmann-La Roche Ltd., Pfizer, Inc., and Xbrane Biopharma AB are some key players operating in the global anti-vascular endothelial growth factor therapeutics industry.

Inspur Information and MEGWARE Build a Leading GPU Cluster for the Friedrich-Alexander-Universität Erlangen-Nürnberg

Retrieved on: 
Tuesday, May 31, 2022
Science, Software, Networks, Research, Hardware, Data Management, Technology, Other Technology, Benchmark, Chemistry, GPU, HPC, Engineering, University, TB, Machine learning, AI, MD, AMBER, Cloud computing, HDR, Science, IDC, Graphics processing unit, Solution, PCI Express, Natural language processing, NAMD, VASP, PyTorch, ML, Biomedical engineering, InfiniBand, Quantum ESPRESSO, Research, AMD, Efficiency, NHR, TOP500, TensorFlow, LAMMPS, Communication, GROMACS, Maintenance, Central processing unit, FAU, Reuters, Video game console, Medical device, Inspur

The advanced GPU cluster, powered by Inspur GPU servers, is fully operational and has far exceeded its original performance targets in machine learning and molecular dynamics.

Key Points: 
  • The advanced GPU cluster, powered by Inspur GPU servers, is fully operational and has far exceeded its original performance targets in machine learning and molecular dynamics.
  • To meet these massive parallel computing needs, NHR@FAU sought to build the largest computing cluster in the universitys history, significantly expanding its research and HPC capabilities.
  • A Europe-wide tender by NHR@FAU led to the selection of Inspur Information and MEGWARE due to their combination of powerful GPU servers, system integration, and optimization expertise.
  • Inspur holds the world's leading GPU server product portfolio, providing industry-leading performance, comprehensive products, and rapid time-to-market capabilities.

DGAP-News: United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis®1 to be Commercialized by Teva as ONGAVIA®

Retrieved on: 
Tuesday, May 17, 2022
Diabetes, Biosimilar, Teva, COO, Central retinal vein occlusion, CNV, RVO, Conditional sentence, Ranibizumab, Retina, ISIN, Patient, MHRA, TASE, Pharmacokinetics, MA, VEGF, COVID-19, Marketing, Health care, United Kingdom, Patent, Medicines and Healthcare products Regulatory Agency, NAMD, Macular degeneration, Partnership, Choroidal neovascularization, III, Multiple sclerosis, Safety, Rheumatoid arthritis, MedImmune, Inc. v. Genentech, Inc., TEVA, Blood, Ophthalmology, Eye, Cancer, Visual impairment, Medication, NYSE, DME, PDR, Generic drug, Pharmaceutical industry, Fine chemical, EU

United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis1 to be Commercialized by Teva as ONGAVIA

Key Points: 
  • United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis1 to be Commercialized by Teva as ONGAVIA
    The issuer is solely responsible for the content of this announcement.
  • Press Release // May 17, 2022
    United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis1, to be Commercialized by Teva as ONGAVIA
    Munich Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (Bioeq) announce, that today the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) in the United Kingdom (UK) for FYB201, a biosimilar to Lucentis (ranibizumab).
  • Teva Pharmaceutical Industries Ltd. (Teva) will serve as the exclusive commercial partner and will market the biosimilar under the brand name ONGAVIA throughout the UK.
  • It inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

Retrieved on: 
Thursday, May 5, 2022
Economics, COVID-19, Congenital hyperinsulinism, Faricimab, GLOBE, DME, Company, Biotechnology, Securities Exchange Act of 1934, Securities Act of 1933, Roche, Food, Safety, Research, Time, CHI, Patient, COPD, Security (finance), MHLW, Diabetic retinopathy, FDA, Form 10-K, Income, Intention, NAMD, Janssen, Terminology, G&A, Ownership, Acquisition, Pharmaceutical industry, Video game, Lithium, Health, Checkmate

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health, reported its first quarter 2022 financial results and provided a recent operations update.

Key Points: 
  • Ended the first quarter of 2022 with cash and restricted cash of $88.6 million and no debt on XOMAs balance sheet.
  • EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health, reported its first quarter 2022 financial results and provided a recent operations update.
  • On April 25, 2022, Roche reported first quarter 2022 financial results, which included initial faricimab sales7.
  • XOMA recorded total revenues of $3.1 million for the first quarter of 2022, compared with $0.4 million in the first quarter of 2021.

DGAP-News: Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG

Retrieved on: 
Friday, April 1, 2022
Crohn's disease, Ranibizumab, Multiple sclerosis, COO, Conditional sentence, CET, Partnership, Investment, III, Biosimilar, Marketing, Patent, Growth, Patient, Press release, II, Macular degeneration, CFO, Ulcerative colitis, Cancer, NAMD, CEO, Board of directors, Psoriasis, ISIN, Inflammation, Federal Executive Boards, Ophthalmology, Rheumatoid arthritis, Intention, Inflammatory Bowel Diseases, Diabetes, Ownership, COVID-19, Supervisory board, Income, Eye, Development, Research and development, Euro, Acquisition, Ustekinumab, IP, MedImmune, Inc. v. Genentech, Inc., Security (finance), Online gambling, Fine chemical, Pharmaceutical industry, Generic drug, EU, FORMYCON, ATHOS, BIOSIMILARS

The acquisition of the biosimilar candidates will give Formycon a significantly higher share in the future revenues from their marketing.

Key Points: 
  • The acquisition of the biosimilar candidates will give Formycon a significantly higher share in the future revenues from their marketing.
  • The intention is for them to contribute sustainably to the value added and to the ongoing growth of the company.
  • The transaction therefore creates key enablers for further expanding Formycon's position as a company operating on the global stage in the growth market for biosimilars.
  • We are confident that Formycon will be in a position to fully exploit its potential in the biosimilars' growth market through this merger."

AMD Instinct™ Expands Ecosystem and Delivers Exascale-Class Technology for HPC and AI Applications

Retrieved on: 
Tuesday, March 22, 2022
Cloud, AMD FireStream, GROMACS, Climate change, CP2K, Forecasting, Research, Micro ISV, Environment, PCI Express, Software, TensorFlow, GLOBE, Solution, AI, CFD, Oak Ridge Leadership Computing Facility, Computer-aided engineering, Dell Technologies, Graphics processing unit, MILC, Instinct, Computer, HPE, Deep learning, HPC, Leadership, ML, Computational fluid dynamics, NASDAQ, AMD, Library, GRID, Oak Ridge National Laboratory, CAE, AMD Accelerated Processing Unit, FP64, Computer-aided, AMBER, Frontier, Ecosystem, Weather, ASUS, Adoption, Molecular modeling on GPUs, Objective Systems Integrators, PyTorch, NAMD, OpenCL, Open Cascade Technology, CSC, Video game console, Cryptocurrency, Gigabyte, Supermicro, Lenovo

SANTA CLARA, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced the availability of the AMD Instinct™ ecosystem with expanded system support from partners including ASUS, Dell Technologies, Gigabyte, HPE, Lenovo and Supermicro, the new AMD Instinct™ MI210 accelerator and the robust capabilities of ROCm™ 5 software. Altogether, the AMD Instinct and ROCm ecosystem is offering exascale-class technology to a broad base of HPC and AI customers, addressing the growing demand for compute-accelerated data center workloads and reducing the time to insights and discovery.

Key Points: 
  • The AMD Instinct MI210 accelerators specifically enable exascale-class technologies for customers who need fantastic HPC and AI performance in a PCIe format.
  • Powered by the AMD CDNA 2 architecture, AMD Instinct MI210 accelerators extend AMD performance leadership in double precision (FP64) compute on PCIe form factor cards1.
  • An open software platform that allows researchers, scientists and engineers to tap the power of AMD Instinct accelerators to drive scientific discoveries, the AMD ROCm platform is built on the foundation of numerous applications and libraries powering top HPC and AI applications.
  • As more purpose-built applications are optimized to work with ROCm and AMD Instinct accelerators, AMD continues to grow its software ecosystem with the addition of commercial ISVs, including Ansys, Cascade Technologies, and TempoQuest.

XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

Retrieved on: 
Tuesday, March 8, 2022
Terminology, CHI, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Employment, Patient, G&A, Income, Food, Security (finance), Biotechnology, Securities Exchange Act of 1934, Safety, Rezolution Pictures, Pancreatic cancer, Glioma, Silicon, Ownership, Compugen, FDA, Company, NAMD, Janssen, COVID-19, Economics, Time, Securities Act of 1933, CEO, Sustainability Accounting Standards Board, History, U.S. Securities and Exchange Commission, Faricimab, Drug Quality and Security Act, Silicon Valley Bank, DME, Insurance, Takeda, Diabetic retinopathy, Health, GLOBE, Form 10-K, Pharmaceutical industry, Lithium, Novartis

In 2021, we received $36.2 million in milestone payments, which allowed XOMA to report positive operating cash-flow for the second consecutive year.

Key Points: 
  • In 2021, we received $36.2 million in milestone payments, which allowed XOMA to report positive operating cash-flow for the second consecutive year.
  • XOMA recorded total revenues of $35.9 million for the fourth quarter of 2021, compared with $27.6 million in the fourth quarter of 2020.
  • For the full year of 2021, XOMA recorded revenues of $38.2 million, compared to $29.4 million for the full year of 2020.
  • After paying its remaining debt obligations in the second quarter of 2021, XOMA has no debt on its balance sheet.

Ophthalmologists Welcome Genentech's Vabysmo, Though Overthrowing Regeneron's Eylea Will Be No Small Feat, Spherix Reports

Retrieved on: 
Thursday, March 3, 2022
Dermatology, Ophthalmology, Patient, HCP, Eye, Pulse, Regeneron Pharmaceuticals, FDA, Awareness, Samsung, Ranibizumab, Celltrion, NAMD, Gastroenterology, AMD, Nephrology, Benchmarking, DME, Diabetic retinopathy, Neurology, Rheumatology, Pharmaceutical industry, Communications satellite, Generic drug, Biogen, Genentech

Insights from the RealTime Dynamix report revealed that market leader, Regeneron's Eylea, continues to reign supreme in nAMD.

Key Points: 
  • Insights from the RealTime Dynamix report revealed that market leader, Regeneron's Eylea, continues to reign supreme in nAMD.
  • According to surveyed ophthalmologists, not only does Regeneron far outpace its competition on manufacturer perceptions and favorability, it's also the clear leader in practice and patient support.
  • So, while there is considerable excitement surrounding Genentech's Vabysmo, the company has significant ground to cover in order to contend with Regeneron.
  • All company, brand or product names in this document are trademarks of their respective holders.

Jeito Capital co-leads $65 million Series A financing in EyeBio

Retrieved on: 
Tuesday, February 22, 2022
BioMed Central, Do Meu Jeito, Entrepreneurship, Saṃsāra, Physician, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Growth, Kate Bingham, Retina, Ophthalmology, Clinical trial, Drug development, United Kingdom, General partnership, Human Development Innovation Fund, AMD, Food, Eye, Senior, LinkedIn, Diabetic retinopathy, Science, NAMD, Leadership, Series, FDA, Eye disease, Genentech, Hoffmann-La Roche, Patient, Roche, Solution, Research, CEO, DME, Pharmaceutical industry

The Series A brings together a team of international executives and investors with an extensive track record for developing ground-breaking ophthalmology therapies.

Key Points: 
  • The Series A brings together a team of international executives and investors with an extensive track record for developing ground-breaking ophthalmology therapies.
  • Jeito co-led the financing with SV Health Investors and Samsara BioCapital, with additional financial backing from MRL Ventures.
  • EyeBio launches with a specific mission: to protect, restore, and improve vision for people who are underserved by available eye disease therapies.
  • Rafale Tordjman, Founder and CEO at Jeito, said: We are pleased to have co-led this financing in EyeBio alongside high-quality international investors.